Key facts
- This page summarizes Meryl Zausner's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2022, 19:19.
Meryl Zausner - 05 Jul 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Director
- Issuer ticker
- MCRB
- Reported as of
- 05 Jul 2022
- Net transaction value
- +$100,000
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2022, 19:19:52 UTC
- Prior SEC filing
- 24 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for Meryl Zausner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Meryl Zausner filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 06 Jul 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: +$100,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
COMMON STOCK
Award
- Transaction value
- $100,000
- Shares
- +31,746
- Change %
- Price
- $3.15
- Shares after
- 31,746
- Date
- 05 Jul 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.